Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

63.75
-0.6600-1.02%
Post-market: 63.800.0505+0.08%18:03 EDT
Volume:6.50M
Turnover:415.21M
Market Cap:129.78B
PE:14.03
High:64.92
Open:64.92
Low:63.73
Close:64.41
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.93
T/O Rate:0.32%
Dividend:2.51
Dividend Rate:3.94%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:5.81
PE(LYR):18.42

Loading ...

Movement Alert|Bristol-Myers Squibb Falls 3.14% in Pre-Market Trading, Trading at $64.2

Market Focus
·
Aug 05

Argus Upgrades Bristol-Myers Squibb to Buy From Hold, Price Target is $75

MT Newswires Live
·
Aug 05

Exclusive-'Never was a Deal to be Done' Between AstraZeneca and Bristol Myers Squibb, Senior Source Close to Matter Says

THOMSON REUTERS
·
Aug 05

Bristol-Myers Squibb Company : Argus Research Raises to Buy from Hold

THOMSON REUTERS
·
Aug 05

Compass Pathways' Q2 Loss Widens on Commercial Readiness Activity Costs

Reuters
·
Aug 05

AstraZeneca deal talks with Bristol Myers remain active, Semafor says

TIPRANKS
·
Aug 05

U.S. Stocks on the MOVE-Expeditors International, Waters, Wayfair

Reuters
·
Aug 05

Bristol Myers Squibb Potential Deal With AstraZeneca Seen Unlikely as Shareholder Views Diverge, RBC Says

MT Newswires Live
·
Aug 04

Johnson & Johnson Names Tom Cavanaugh EVP, Worldwide Chairman of Innovative Medicine as Taubert Retires

Reuters
·
Aug 04

Bristol-Myers Squibb Announces Dividend of R$ 2.11 Per Unit for Q3 2026

Reuters
·
Aug 04

Bristol Myers Poised to Give up Modest Gains Tied to AstraZeneca Deal Talks

Reuters
·
Aug 04

Daiwa Securities Adjusts Bristol-Myers Squibb PT to $66 From $53, Maintains Neutral Rating

MT Newswires Live
·
Aug 04

UK's ConvaTec Meets Prelim H1 Revenue Estimates

Reuters
·
Aug 04

More Biotech M&A is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not

Dow Jones
·
Aug 04

A $400 Billion Pharma Merger? RBC Says Don't Bet On It

Options & Short Sell
·
Aug 04

PRESS Digest-British Business - August 4

Reuters
·
Aug 04

An AstraZeneca, Bristol Myers Squibb Merger Could Create a Cancer-Drug Giant, but Analysts Call it 'odd'

Dow Jones
·
Aug 04

Bristol-Myers Squibb is Maintained at Neutral by Citigroup

Dow Jones
·
Aug 04

TD Cowen sees no strategic logic in an AstraZeneca-Bristol Myers merger

TIPRANKS
·
Aug 04

FTSE 100 Dips as AstraZeneca Slides on Bristol Myers Tie-up Talks

Reuters
·
Aug 04